Spots Global Cancer Trial Database for RTX-224 Monotherapy in Patients With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: RTX-224 Monotherapy in Patients With Solid Tumors
Official Title: A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors
Study ID: NCT05219578
Interventions
Study Description
Brief Summary: This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors.
Detailed Description: This is a Phase 1, open label, multicenter, multidose, first-in-human (FIH), dose escalation and expansion to determine the safety and tolerability, recommended phase 2 dose, and pharmacology, and antitumor activity of RTX-224 in adult patients with persistent, recurrent, or metastatic, unresectable solid tumors. The study will include a monotherapy dose escalation phase followed by an expansion phase.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth, Scottsdale, Arizona, United States
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California San Francisco Health, San Francisco, California, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
